Genetic engineering concept. Medical science. Scientific Laboratory.
image-

APDN to Establish N. America’s 1st Enzymatic Large-Scale cGMP DNA Manufacturing Capacity in New York

Posted on

– Planned Doubling of Current DNA Production Capacity will Enable Company to Support Customers from Early-stage Drug Discovery Through Late-phase Clinical Trials – – Expansion Plans Catalyzed by Growing Industry Demand for LinearDNA™,  Repeat and New Proof-of-Concept Orders from Customers with Long-Term Requirements for cGMP DNA – Operational Commencement Expected in 2H CY2023 – STONY […]

Read More email

image-

Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date

Posted on

STONY BROOK, N.Y. – October 10, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, announced today that it received its largest single purchase order for LinearDNA™ valued above the mid-six-figures. The order was placed under a long-standing supply agreement for the bulk manufacture of LinearDNA for a […]

Read More email

image-

APDN’s Biotherapeutics Subsidiary Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets

Posted on

Promising Results Support Further Development of LinearDNA as a Next Generation Vaccine Platform STONY BROOK, N.Y. – September 26, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA’ or the “Company”), a leader in polymerase chain reaction (PCR”)-based technologies, today announced the publication of a manuscript, co-authored with international academic and industry scientists, containing […]

Read More email

image-

Applied DNA and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications

Posted on

– Agreement Leverages Company’s Ability for Intramuscular Delivery of LNP-Encapsulated LinearDNA-based Therapies for Veterinary Therapeutic and Prophylactic Applications – STONY BROOK, N.Y. and ITHICA, N.Y. – September 8, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA’ or the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, and the Cornell University College of […]

Read More email

image-

LinearDNA™ Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)

Posted on

– Use of LNP Simplifies Administration of LinearDNA-based Therapies, Potentially Enabling Their Application in Large Scale – STONY BROOK, N.Y. – August 10, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, today announced that LineaRx, the Company’s majority-owned biotherapeutics subsidiary, has for the first time […]

Read More email

image-

Applied DNA Biotherapeutics Subsidiary LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development

Posted on

– Separately, LineaRx Announces Successful Expression In Vitro of Vaccine Candidate Encapsulated with Lipid Nanoparticles –  STONY BROOK, N.Y. July 25, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, today announced the publication of a manuscript containing data demonstrating that a linearDNA vaccine successfully elicited neutralizing antibodies and cellular […]

Read More email

image-

Applied DNA Biotherapeutics Subsidiary LineaRx to Present Data Showcasing Advantages of its Enzymatically Produced LinearDNA as Substitute for Plasmid DNA in IVT mRNA Production at the 2nd Annual mRNA-Based Therapeutics Summit

Posted on

– Industry Leaders Will Learn How LinearDNA Can Significantly Improve RNA Manufacturing Speed, Simplicity, and Scalability in Comparison to Plasmid DNA – STONY BROOK, N.Y. – July 22, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based technologies, today announced that Dr. James A. Hayward, president and CEO of Applied […]

Read More email

image-

Applied DNA Launches Initiatives to Expand Awareness of LinearDNA™ Platform as an Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website

Posted on

STONY BROOK, N.Y. – June 29, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, announced the formal launch of business development initiatives to expand the biotherapeutics industry’s awareness of the LinearDNA™ platform (the “platform”) as an alternative to current plasmid-based (pDNA) production processes used in the […]

Read More email

image-

Positive Preclinical Data for LinearDNA™ as Novel Cancer Vaccine Strategy

Posted on

STONY BROOK, N.Y. and ROME, ITALY – June 6, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and its program development partner, EvviVax, S.R.L. (“EvviVax”), today announced the peer-reviewed publication of preclinical animal data in The Journal of Experimental & Clinical Cancer Research that supports the use of Applied DNA’s LinearDNA™ platform […]

Read More email

image-

Spindle Biotech Research Collaboration on mRNA Production System

Posted on

STONY BROOK, N.Y. and TORONTO, CANADA – March 14, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and Spindle Biotech Inc. (“Spindle Biotech”), a company focused on the development of a novel, high yield, and low-cost RNA production systems, today announced that the two companies have executed […]

Read More email

image-

Beefing Up Cancer Treatments, With A Vaccine In Sight

Posted on

Cancer crusade: Stony Brook-based Applied DNA Sciences and Italian biopharma EvviVax are one step closer to a bona fide DNA-based cancer vaccine. FEBRUARY 17, 2022 By GREGORY ZELLER // New vaccines produced in part by a progressive Long Island biotech could significantly increase the efficacy of existing cancer treatments. The potential breakthrough – detailed this month in […]

Read More email

image-

Applied DNA and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

Posted on

– First Published Study Demonstrates LinearDNA Pan-Cancer and Colon Cancer Neoantigen – – Targeted Vaccines Elicit a Therapeutic Immune Response in Animal Cancer Models – – LinearDNA Vaccines Elicits Strong Antigen-specific Immune Responses and Significantly Reduces Tumor Growth – – Manuscript Summarizing Findings Posted to Preprint Server and Submitted for Peer-Reviewed Publication – STONY BROOK, […]

Read More email

image-

Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA

Posted on

STONY BROOK, N.Y. – November 15, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, and its majority-owned subsidiary LineaRx, Inc., a manufacturer of LinearDNA™ via PCR for nucleic acid therapeutics and diagnostics, today announced the receipt of repeat orders from […]

Read More email

image-

Research Publication Demonstrates Utility of Applied DNA’s LinearDNA™ in Non-Viral CAR T Manufacturing Systems

Posted on

Preclinical Study Details Application of LinearDNA Suitable for the Cost-Effective Production of CAR T Cells Results Demonstrate that CAR19 T-cells Manufactured with LinearDNA Have Similar Efficacy to CAR19 T-cells Manufactured with Plasmid DNA STONY BROOK, N.Y. – November 9, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction […]

Read More email

image-

Research Publication Demonstrates Utility of Applied DNA’s LinearDNA™ in Non-Viral CAR T Manufacturing

Posted on

STONY BROOK, N.Y. – November 9, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced the publication of a study in Molecular Therapy: Methods and Clinical Development on a methodology for the manufacture of novel types of […]

Read More email

image-

Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, P1, and B.1.526 Variants and Sets August 2021 Mink Challenge Trial Launch

Posted on

STONY BROOK, N.Y. and ROME, ITALY – June 7, 2021 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. (“Evvivax”), today announced results from an in vitro neutralization study of sera from the trial cohort comprised of 11 domestic felines vaccinated […]

Read More email

image-

Applied DNA, Evvivax Announce LinearDNA™ Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines

Posted on

Applied DNA and Evvivax Announce that LinearDNA™ COVID-19 Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines Manufactured by an enzyme and without bacteria, LinearDNA vaccine candidate is virus-free, plasmid-free DNA Vaccine candidate induced neutralizing titers in 100% of trial cohort Based on positive study results, companies plan to accelerate […]

Read More email

image-

Clinical Trial to Evaluate LinearDNA COVID-19 Vaccine Candidate for Felines

Posted on

– COVID Feline Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse Models – – Clinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines –STONY BROOK, N.Y. & ROME. March 2, 2021. Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), […]

Read More email

image-

Applied DNA Develops Linear DNA Veterinary COVID-19 Vaccine

Posted on

Applied DNA Achieves Program Milestone in Development of  Linear DNA Veterinary COVID-19 Vaccine – Qualifies Freeze-Dried Version of LinearDNA™ COVID-19 Vaccine Candidate Ahead of Initiation of Feline Clinical Trial – –  Reconstituted Vaccine Candidate Demonstrates Potency, Validating Easy Shipment in Dry State – – Feline Clinical Trial On-Track to Begin by March 31, 2021 – […]

Read More email

image-

Applied DNA, EvviVax, and GVS Receive Regulatory Approval to Conduct Veterinary Clinical Trial for Linear COVID-19 Vaccine Candidate

Posted on

Trial Redesigned to Accelerate Development of Clinical Path to Potential USDA APHIS Conditional License for Commercial Veterinary Sales STONY BROOK, N.Y. – November 30, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, EvviVax, S.R.L. (“EvviVax”), a spin-off of Takis Biotech with expertise […]

Read More email

image-

Applied DNA Announces Linear DNA Orders from New Contract Research Customers for Use in RNA Vaccine and Adeno-Associated Virus Applications

Posted on

STONY BROOK, N.Y. – November 2, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that it received orders for its linear DNA to be evaluated in an RNA vaccine and Adeno-Associated Virus (AAV) production from two new contract research customers, […]

Read More email

image-

APDN and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate

Posted on

STONY BROOK, N.Y. – September 16, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, preclinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced that it and Evvivax, S.R.L., a spin-out of Takis Biotech […]

Read More email

image-

Applied DNA Positions LinearDNA™ Platform as the Next Generation Manufacturing Platform for Adeno-Associated Virus-based Gene Therapies Through New Patent Filing

Posted on

Patent Application Relates to Production of Adeno-Associated Virus (AAV) via Use of LinearDNA™ Amplicons; AAV Viral Vectors Used in Gene and Redirected Cell Therapies; Current Production of AAV Relies Heavily on Use of Plasmid-derived DNA STONY BROOK, N.Y. – August 17, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader […]

Read More email

image-

Applied DNA and Takis Report Positive Preclinical Results from LineaDNA™ Vaccine Candidates for COVID-19

Posted on

Demonstrates Evidence of Production of Antibodies and T Cell Responses in Mice: Shows Strong Antibody Responses, Activation of Sustainable T-Cell Responses, Presence of IgG in Lungs STONY BROOK, N.Y. – July 17, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, […]

Read More email

image-

Applied DNA Secures Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates

Posted on

STONY BROOK, N.Y. – June 9, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company,” “our”) announced today it secured a $40,000 economic development grant from National Grid to support the Company’s efforts associated with the manufacture of COVID-19-related therapeutics and diagnostics programs. National Grid is one of the largest investor-owned […]

Read More email

image-

Applied DNA Provides Update on Linear-DNA COVID-19 Vaccine Candidates Development Program

Posted on

STONY BROOK, N.Y. – June 8, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the  “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today provided an update related to the development of […]

Read More email

image-

Applied DNA to Participate in Maxim Group’s COVID-19 Virtual Conference Series on May 27

Posted on

STONY BROOK, N.Y., May 21, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, announced that Dr. James Hayward, president & CEO, will participate on a […]

Read More email

image-

Applied DNA and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals

Posted on

Beyond expectations, a single injection of DNA in mice induced antibodies that block the infection of cultured human cells by SARS-CoV-2 STONY BROOK, N.Y. and Rome, Italy – May 4, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company” or “we/our”) today announced with its COVID-19 vaccine development partner Takis Biotech […]

Read More email

image-

Italian Biotech Startup Racing To Develop A Coronavirus Vaccine

Posted on

Four days before the first cases of COVID-19 were confirmed in Italy on January 31, a small biotech firm in the outskirts of Rome announced it was pivoting its business. Researchers at Takis Biotech, which had been focused on cancer treatments, would instead set about developing a vaccine for the rapidly spreading coronavirus. With the virus […]

Read More email

image-

Applied DNA High-Sensitivity and High-Throughput COVID-19 Diagnostic Kit Enters Validation Process in Partnership with Stony Brook University Hospital

Posted on

Paves Path for Application to FDA for Emergency Use Authorization before end of April 2020; Company providing high-throughput RNA-extraction robotics and enhanced-sensitivity RT-qPCR assay with goals to diminish false negatives, quantify viral loads and enhance testing volumes for the region STONY BROOK, N.Y. April 21, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” […]

Read More email

image-

LI Biotech Speeds COVID-19 Vaccine Candidates To Italy

Posted on

Cure bet: If vaccine candidates prepared by Applied DNA’s LinearDNA manufacturing system perform as well as plasmid-based candidates prepared by Italian biopharma Takis Biopharma, the cross-Atlantic collaboration may be on to something. APRIL 15, 2020 By GREGORY ZELLER // With preliminary lab tests looking good, an innovative Long Island biotech is rushing a quintet of […]

Read More email

image-

Applied DNA Ships COVID-19 LinearDNA™ Vaccine Candidates to Italian Development Partner to Begin Preclinical Animal Testing

Posted on

STONY BROOK, N.Y., and ROME, ITALY. April 15, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced that it has completed design qualification, production […]

Read More email

image-

Applied DNA to Speak on COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5

Posted on

STONY BROOK, N.Y., April 14, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced its participation at Maxim Group’s Infectious Disease Virtual Conference on […]

Read More email

image-

Applied DNA Ships LinearDNA™ to Another Development Customer

Posted on

STONY BROOK, N.Y., March 26, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, announced today that it has shipped two CAR T amplicons proprietary to […]

Read More email

image-

APDN Secures Top-20 Pharmaceutical Manufacturer as Drug Development Customer

Posted on

STONY BROOK N.Y., March 20, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and liquid biopsies for cancer diagnostics, announced today that it has signed a Research Agreement (the “Agreement”) with a global […]

Read More email

image-

Applied DNA Leverages COVID-19 Vaccine Development and Proprietary Linear DNA Manufacturing Capability to Design a High Sensitivity Diagnostic Kit for Virus Detection

Posted on

– Assay under development uses PCR-based detection of viral sequences that code for the Spike protein that is also the target of the Company’s vaccine candidate with Takis Biotech –– messenger RNA abundance for Spike in host cells should yield high sensitivity – STONY BROOK, N.Y., March 19, 2020 – Applied DNA Sciences Inc. (NASDAQ: […]

Read More email

image-

Applied DNA COVID-19 Collaboration Partner Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-Clinical Models

Posted on

STONY BROOK, N.Y., March 18, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”) today announced that its COVID-19 collaboration partner, Takis Biotech, a Rome, Italy-based a company focused on the development of cancer vaccines founded by scientists from Merck Research Laboratories, has received approval from the Italy’s Ministry of Health to begin a […]

Read More email

image-

Stony Brook firm working on coronavirus vaccine

Posted on

A Stony Brook anti-counterfeiting company is seeking to adapt its DNA expertise to create a coronavirus vaccine with an Italian biotechnology partner. Applied DNA Sciences Inc. on Monday announced that it is expanding its alliance with Rome-based Takis Biotech on four potential vaccines to test on animals. In February, the companies announced a joint development […]

Read More email

image-

Applied DNA, Takis Biotech design four Covid-19 vaccine candidates

Posted on

The PCR-produced linear DNA is expected to accelerate vaccine production. Applied DNA Sciences and Takis Biotech have designed four Covid-19 vaccine candidates to help protect against the novel coronavirus. The companies plan to manufacture the DNA vaccine candidates using PCR-based DNA (LinearDNA) manufacturing systems for preclinical testing in animals. Last month, Applied DNA Sciences subsidiary LineaRx […]

Read More email

image-

Applied DNA Speeds Coronavirus Vaccines Toward Tests

Posted on

Driving the spike: The way COVID-19 attaches to host cells — and Applied DNA’s unique DNA-production abilities — could lead to a vaccine against the dreaded coronavirus. MARCH 2, 2020 By GREGORY ZELLER // Just weeks after announcing an expanded international collaboration targeting the menacing novel coronavirus, Applied DNA Sciences is preparing to mass-produce four potential vaccines. Leveraging the […]

Read More email

image-

Applied DNA Sciences (NASDAQ: APDN) Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed

Posted on

STONY BROOK, N.Y., and ROME, ITALY – March 2, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and liquid biopsies for cancer diagnostics, and Takis Biotech (“Takis”), a company focused on the development of […]

Read More email

image-

Applied DNA To Speed Up Coronavirus Countermeasures

Posted on

By GREGORY ZELLERLook out, coronavirus – Applied DNA is coming for you. Adding to its growing portfolio of cutting-edge Polymerase Chain Reaction-based projects, Stony Brook-based Applied DNA Sciences is expanding its Joint Development Agreement with Italian R&D company Takis Biotech, with the headline-making 2019-nCoV in their sights. Already hot on the trail of new cancer vaccines, the partners will […]

Read More email

image-

Applied DNA, Takis Biotech partner on coronavirus vaccine

Posted on

The PCR-produced linear DNA is expected to accelerate vaccine production. Applied DNA Sciences has extended its partnership with Takis Biotech to include the development of a vaccine for 2019-nCoV coronavirus. LineaRx, a subsidiary of Applied DNA, will work with Takis Biotech on preclinical development of a linear DNA vaccine based on polymerase chain reaction (PCR). […]

Read More email

image-

Applied DNA Sciences Subsidiary, LineaRx, and Takis Biotech Collaborate for Development of a Linear DNA Vaccine Candidate Against Wuhan Coronavirus 2019-nCoV

Posted on

Expanded Joint Development Agreement Serves as Basis for Preclinical Linear DNA Vaccine; Linear DNA Platform Will be the Production Framework STONY BROOK N.Y., February 7, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic […]

Read More email

image-

APDN Subsidiary, LineaRx, Inc., Sign Licensing Agreement with LifeSensors

Posted on

Applied DNA Subsidiary, LineaRx, Inc., Sign Licensing Agreement with LifeSensors LineaRx will incorporate LifeSensors’ SUMO-fusion technologies to maximize protein expression of PCR-produced Linear DNA STONY BROOK N.Y., January 13, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its majority-owned subsidiary focused on next-generation biotherapeutics […]

Read More email

image-

Applied DNA to Hold Investment Community Meetings During the JP Morgan 38th Annual Healthcare Conference and Present at the Biotech Showcase 2020

Posted on

STONY BROOK, N.Y. – January 10, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and liquid biopsies for cancer diagnostics, today announced that CEO Dr. James A. Hayward and leadership of the […]

Read More email

image-

LineaRx signs agreement with TYME Technologies

Posted on

Applied DNA Sciences announced that LineaRx, the Company’s majority-owned subsidiary focused on next-generation biotherapeutics and diagnostics, has signed a definitive agreement with Tyme Technologies, to supply the Company’s Vita-Assay™ invasive Circulating Tumor Cell (iCTC) capture assay and associated services for use in the pivotal stage of the TYME-88-PANC clinical trial for patients with third-line pancreatic […]

Read More email

image-

LineaRx Signs Agreement with TYME Technologies for Functional ICTC Assay Services in Pancreatic Cancer Trial

Posted on

STONY BROOK, N.Y., November 26, 2019 –  Applied DNA Sciences, Inc. (NASDAQ: APDN; the “Company” or “Applied DNA”) announced today that LineaRx, Inc., the Company’s majority-owned subsidiary focused on next-generation biotherapeutics and diagnostics, has signed a definitive agreement with Tyme Technologies, Inc. to supply the Company’s Vita-Assay™ invasive Circulating Tumor Cell (iCTC) capture assay and associated services […]

Read More email

image-

Applied DNA Sciences Reports 14 Development Customers for its Linear DNA Manufacturing Platform

Posted on

STONY BROOK, N.Y., November 25, 2019 –  Applied DNA Sciences, Inc. (NASDAQ: APDN, Applied DNA, “the Company”) announced today that LineaRx, Inc., its majority-owned subsidiary focused on next-generation biotherapeutics and diagnostics, has grown its customer base to fourteen companies currently testing its linear DNA manufacturing platform for the development of nucleic acid-based therapies and diagnostics.  The Company […]

Read More email

image-

iCTC Platform Shows Superior Correlation over PSA as a Biomarker

Posted on

STONY BROOK, N.Y., October 1, 2019 – LineaRx, Inc., the majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) focused on next-generation biotherapeutics, announced today that its invasive Circulating Tumor Cells (iCTCs) platform demonstrated superior correlation over Prostate Specific Antigen (PSA) in an ongoing Phase II trial in recurrent prostate cancer. Most notably, the concentration of rare iCTCs […]

Read More email

image-

Linear DNA Combo Shows Punch In Cancer Fight

Posted on

By GREGORY ZELLER //SEPTEMBER 19, 2019 Mark another impressive victory for LineaRX, this time in a two-front battle against cancer. The Stony Brook-based biotech with innovation in its DNA (literally) has lent its unique DNA-sequencing technology to two vaccine-candidate tests run by Italian R&D company Takis Biotech, which is hot on the trail of new therapeutic […]

Read More email

image-

LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction

Posted on

STONY BROOK, N.Y., September 19, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its majority-owned subsidiary focused on next-generation biotherapeutics, and its collaborators Takis/Evvivax have completed pre-clinical animal studies of two vaccine candidates produced with linear DNA. Tests of both vaccines in mouse […]

Read More email

image-

For Applied DNA, New Blood — And A Shot In The Arm

Posted on

In the flow: A key acquisition, new blood-analyzing tech and critical Medicare/Medicaid reimbursements for T-cell therapies have Applied DNA Sciences and 2018 spinoff LineaRX pumped up. AUGUST 12, 2019 By GREGORY ZELLER // Just 11 months after spinning off from its parent company, a Stony Brook startup with expansion in its DNA has made its […]

Read More email

image-

Medicare Coverage of CAR T-Cell Therapy Holds Positive Implications for LineaRx

Posted on

STONY BROOK, NY. August 12, 2019 – LineaRx, Inc. (“LineaRx”), a majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced that, in a decision rendered on August 7, 2019, the Centers for Medicare and Medicaid Services (CMS) approved chimeric antigen receptor (CAR) T-cell therapies that fit the CMS criteria […]

Read More email

image-

LineaRx Acquires Cancer Cell Assets and Intellectual Property of Vitatex

Posted on

August 8, 2019 NEW YORK — LineaRx said today that it has acquired the assets and intellectual property of Vitatex, a developer of invasive circulating tumor cell (iCTC) analysis technologies. According to LineaRx — an Applied DNA Sciences subsidiary formed around technologies for DNA design, manufacture, and chemical modification by large scale PCR — Vitatex’s technologies […]

Read More email

image-

LineaRx Acquires Assets and Intellectual Property of Vitatex

Posted on

STONY BROOK, NY. August 8, 2017 – LineaRx, Inc. (“LineaRx”), a wholly-owned subsidiary of Applied DNA Sciences, Inc. (“Applied DNA or the Company,” NASDAQ: APDN), announced today that it has acquired the physical assets and Intellectual Property (IP) of Vitatex Inc. (“Vitatex”), a private biotechnology company focused on advancing personalized medicine with an innovative solution […]

Read More email

image-

LineaRx Receives Multiple Orders for Linear DNA for Use in Therapeutic Development

Posted on

STONY BROOK, NY. July 1, 2019 – LineaRx, Inc., a wholly-owned subsidiary of Applied DNA Sciences, Inc. (“Applied DNA or the Company,” NASDAQ: APDN), announced today that it has received multiple purchase orders, from several major developers of gene and cell therapies, for its proprietary and patented large-scale, polymerase-chain-reaction (PCR)-produced linear DNA. LineaRx believes this […]

Read More email

image-

LineaRx to Support Therapy Development for Neurodegenerative Diseases

Posted on

STONY BROOK, NY. June 26, 2019 – LineaRx, Inc. a wholly-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today that it has shipped multiple customized linear DNA amplicons to Evotec SE, a well-known therapeutic development company, to support their research efforts related to neurodegenerative diseases such as Huntington’s, Parkinson’s or Alzheimer’s disease. DNA […]

Read More email

image-

LineaRx Anticipates Expansion in Diagnostics Market

Posted on

STONY BROOK, NY. May 21, 2019 – LineaRx, a wholly-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN), announced that it is in process of designing new, custom amplicons for an existing customer in the in vitro diagnostics market. The diagnostic assay is expected to be available and qualified in 2020, potentially resulting in increasing […]

Read More email

image-

LineaRx Achieves Higher Expression and Survival Rates in Human T Cells

Posted on

LineaRx Achieves Higher Expression and Survival Rates in Human T Cells Transfected Non-Virally with Linear DNA STONY BROOK, NY. April 29, 2019 – LineaRx, Inc. ( the “Company”) a wholly owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today that it has improved expression levels and survival rates of linear DNA constructs delivered […]

Read More email

image-

Linear DNA Crosses the Line between Tags and Therapeutics

Posted on

Short fragments of linear DNA are used for molecular tagging in a variety of industries, from textiles to pharmaceuticals, to provide product authentication and ingredient traceability. Applied DNA Sciences is now translating its expertise in the molecular tagging industry to the biopharma industry. Its subsidiary, LineaRx, is manufacturing large, gene-sized fragments of linear DNA for […]

Read More email

image-

LineaRx Achieves Anti-CD19 Expression in Human CAR T Cells via Plasmid-Free Platform

Posted on

STONY BROOK N.Y., April 8, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that LineaRx, (the “Company”), its subsidiary focused on next-generation biotherapeutics, has achieved anti-CD-19 CAR (Chimeric Antigen Receptor) expression in human T Cells via its proprietary, non-viral, plasmid-free (NVPF) manufacturing platform. To the Company’s knowledge, this seminal event represents the first […]

Read More email

image-

Applied DNA Subsidiary LineaRx and Takis/Evvivax Progress Linear DNA for Use as Cancer Vaccine Candidates

Posted on

STONY BROOK, N.Y., March 1, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, will ship TK7 and ConTRT amplicons to Takis/Evvivax next week as part of the companies’ Joint Development Agreement (“JDA”) entered […]

Read More email

image-

LineaRx to Announce DNA Vaccine Preclinical Data and Efficacy of In-Licensed CAR T Therapy

Posted on

[vc_column_text el_class=”graphic”]STONY BROOK N.Y., December 4, 2018 – LineaRx, Inc., the biotherapeutics company based on the use of large-scale production of gene-sized DNA by Polymerase Chain Reaction (“PCR”) and dedicated to revolutionizing biotherapeutics for the masses in affordability, availability, time-to-market, and reducing the risk associated with virally mediated therapy, and a wholly-owned subsidiary of Applied […]

Read More email

image-

LineaRx Provides Cost and Quality Advantages to Technogenetics

Posted on

STONY BROOK, NY. November  7, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”  or the “Company”) has been providing linear DNA to Technogenetics (Shanghai Kehua Bio-Engineering Co., Ltd-KHB group) that produces and sells kits to detect autoimmunity and infectious diseases. […]

Read More email

image-

At LineaRX, Putting The Horsepower Behind The CAR T

Posted on

Unique position: With its next-level ability to produce DNA constructs, Stony Brook startup LineaRX is looking to speed up production of critical, anti-cancer chimeric antigen receptor modified T cell (or CAR T) therapies. By GREGORY ZELLER OCTOBER 16, 2018 Marking a big step in the war against cancer, a Stony Brook-based startup has initiated pre-clinical […]

Read More email

image-

Non-Viral, Plasmid-Free CAR T-Manufacturing Platform Begins Preclinicals

Posted on

Streamlined manufacturing processes could yield reduced cost and lead times, lessening patient morbidity and mortality through shorter “vein-to-vein” times. [Applied DNA Sciences] By MaryAnn Labant A rapidly emerging immunotherapy approach, adoptive cell transfer (ACT), collects and uses a patient’s own immune cells to treat their cancer. One methodology, Chimeric Antigen Receptor T-Cell (CAR T-cell) therapy, has advanced […]

Read More email

image-

LineaRx Licenses CAR T Drug Candidate, Initiates Pre-Clinical Development of Non-viral, Plasmid-free CAR T Manufacturing Platform

Posted on

Applied DNA Subsidiary LineaRx Licenses CAR T Drug Candidate and Initiates Pre-Clinical Development of Non-viral, Plasmid-free CAR T Manufacturing Platform Novel DNA Manufacturing Platform Pioneering a New Generation of Faster, More Affordable CAR T Therapeutics. Offering Available to CRO/CMO Customers STONY BROOK, N.Y., October, 16, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” […]

Read More email

image-

LineaRx Secures New RNA Therapeutics Customers for Contract Research Services

Posted on

LineaRx offers simplified manufacturing path to RNA Biotherapeutics via linear DNA STONY BROOK N.Y., October 1, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx” ” or the “Company”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has secured multiple new developers […]

Read More email

image-

LineaRx to Collaborate with Italian Companies Takis and Evvivax on Cancer Vaccines

Posted on

Published: Sep 20, 2018 By Mark Terry LineaRx, a subsidiary of Applied DNA Sciences, has entered into a Joint Development Agreement with Takis SRL and Evvivax SLR. They will focus on developing anti-cancer vaccines. Under the terms of the deal, LineaRx and Takis and Evvivax will work together to develop linear DNA expression vectors of two of Takis/Evvivax’s anti-cancer vaccine candidates. They will […]

Read More email

image-

Applied DNA Subsidiary, LineaRx, Inc. Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines

Posted on

Collaboration Seeks to Develop PCR-produced Linear DNA as a Safer Expression Vector for Vaccines STONY BROOK N.Y., September 20, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement (the “Agreement”) with Takis […]

Read More email

image-

With New Spinoff, Biotech Goes All-In On DNA Sales

Posted on

SEPTEMBER 18, 2018 By GREGORY ZELLER A Stony Brook biotech with a growing international reputation for supply-chain security has spun off a new company focused on DNA modification and production. With an eye on exploding biotherapeutic fields, Stony Brook-based Applied DNA Sciences has spun its DNA-manufacturing business into a new company, LineaRx. Stony Brook-based Applied DNA […]

Read More email

image-

APDN Forms Subsidiary, LineaRx, to Develop DNA for Biotherapeutics

Posted on

STONY BROOK N.Y., September 18, 2018 – Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, announced today the formation of LineaRx, Inc., a wholly owned subsidiary. Its purpose is to commercialize the Company’s extensive experience in the design, manufacture and chemical modification of DNA by […]

Read More email

image-

APDN Presenting Linear DNA for Gene Therapy at Boston Immuno-Oncology Summit

Posted on

Applied DNA Presenting Linear DNA for Gene Therapy at Boston Immuno-Oncology Summit High-Expression Amplicons Facilitate Non-Recombinant Gene Therapies Hold the Potential to Serve as an Alternative to Plasmids and Viral Vectors STONY BROOK N.Y., August 27, 2018 – Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA,”), the leader in large-scale PCR-based DNA manufacturing, will present […]

Read More email